Historically, Vizient has published the Pharmacy Market Outlook biannually. This year, we are introducing the Spend Management Outlook, which integrates the comprehensive insights from the Pharmacy Market Outlook with the Vizient Budget Impact Report. This new report enhances strategic planning by aligning pricing projections across the healthcare supply chain and providing key market insights. Dr. Carina Dolan, Associate Vice President of Clinical Oncology, Pharmacoeconomics, & Market Insights, and Jeff King, Director of Research and Intelligence at Vizient, join Program Host Carolyn Liptak to discuss the unique features and critical importance of the new Spend Management Outlook.

Guest speakers:

Carina Dolan, Pharm. D., MS Pharm, BCOP

Associate Vice President, Clinical Oncology, Pharmacoeconomics and Market Insights

Vizient

Jeff King

Research and Intelligence Director

Vizient

Host:

Carolyn Liptak, MBA, BS Pharm

VerifiedRx Host

Show Notes:

[01:06-01:56] Jeff’s background and role

[01:57-02:50] The transition from Pharmacy Market Outlook and Budget Impact Report to Spend Management Outlook

[02:51-03:28] Defining spend management

[03:29-04:43] Key insights into spend management categories med-surg and laboratory

[04:44-06:01] Key insights into spend management categories Capital equipment and physician preferences insights

[06:02-07:23] Enhancements to pharmacy projections of this edition

[07:24-08:39] Spend management projection methodology

[08:40-09:34] The spend management projections

Links | Resources:

Spend Management Outlook

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Android

RSS Feed

We anticipate there will be some policy changes and important issues to watch with the inauguration of the 47th president of the United States. Vizient’s office of public policy and government relations monitors, educates and advocates on key items of interest. They share informative updates, comment on proposed rules from agencies like the Centers for Medicare and Medicaid Services and work with Congress on legislative priorities. Jenna Stern, Associate Vice President of Regulatory Affairs and Public Policy at Vizient joins Program Host Carolyn Liptak to discuss the change over.

Guest speakers:

Jenna Stern

Associate Vice President of Regulatory Affairs and Public Policy

Vizient

Host:

Carolyn Liptak, MBA, RPh

VerifiedRx Host

Show Notes:

[00:56-01:15] Jenna’s background

[01:16-02:38] Anticipation in DC since November

[02:39-04:26] What we should anticipate with the new Congress

[04:27-08:10] Trade and Tariffs

[08:11-10:37] What we should anticipate with the Executive Branch

[10:38-12:48] Policies to watch during transition

[12:48-13:34] Where listeners go for more information

[13:34-16:12] What issues are important to the new Congress

Links | Resources:

Vizient Public Policy and Government Relations

Vizient advocacy letters and Congressional statements

Legislative and regulatory summaries

China Tariffs document

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Android

RSS Feed

Human rabies cases are fortunately rare in the US. Access to pre- and post-exposure prophylaxis, and domestic animal vaccination programs, drive this public health success. This comes at a financial and human resources cost. Dr. Kyle Weant, clinical assistant professor and an emergency medical clinical pharmacy specialist at the University of South Carolina College of Pharmacy and Dr. Philippe Mentler, senior consulting director, join host Gretchen Brummel to discuss the use of rabies immune globulin and rabies vaccine in patients who have been exposed and provide treatment pearls for frontline pharmacy practioners.

Guest speakers:

Kyle Weant, PharmD, BCPS, BCCCP, FCCP

Clinical Assistant Professor and an Emergency Medical Clinical Pharmacy Specialist

University of South Carolina College of Pharmacy

Philippe Mentler, PharmD, BCPS

Senior Consulting Director

Vizient

Host:

Gretchen Brummel, PharmD, BCPS

Show Notes:

[00:54-01:17] Kyle’s background information

[01:18-03:31] Rabies as a disease

[03:32-05:13] Public Awareness

[05:14-07:06] Options right now for post-exposure prophylaxis

[07:07-10:01] Thoughts on dose rounding

[10:02-10:13] Is rabies immunoglobulin considered an essential medication that everyone should stock in their hospital pharmacy

[10:14-11:30] Who should be administering these drugs? And who's ensuring follow up of these patients?

[11:31-14:31] Potential pitfalls in patient management

[14:32-18:12] What should our frontline pharmacy staff know about post-exposure prophylaxis

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Android

RSS Feed